Chargement en cours...
CGRP monoclonal antibody for preventive treatment of chronic migraine: An update of meta‐analysis
BACKGROUND: CGRP monoclonal antibody (mAb) is a promising preventive treatment for episodic migraine and has been approved by US FDA recently. But the treatments for chronic migraine are rare. Therefore, we performed meta‐analysis to assess the efficacy and safety of CGRP mAbs in preventing chronic...
Enregistré dans:
| Publié dans: | Brain Behav |
|---|---|
| Auteurs principaux: | , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
John Wiley and Sons Inc.
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6379644/ https://ncbi.nlm.nih.gov/pubmed/30656853 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/brb3.1215 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|